JP2015505966A - 循環腫瘍細胞を特定するための装置、システム、及び方法 - Google Patents
循環腫瘍細胞を特定するための装置、システム、及び方法 Download PDFInfo
- Publication number
- JP2015505966A JP2015505966A JP2014546147A JP2014546147A JP2015505966A JP 2015505966 A JP2015505966 A JP 2015505966A JP 2014546147 A JP2014546147 A JP 2014546147A JP 2014546147 A JP2014546147 A JP 2014546147A JP 2015505966 A JP2015505966 A JP 2015505966A
- Authority
- JP
- Japan
- Prior art keywords
- well
- cell
- cells
- ctc
- sample
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 title claims abstract description 114
- 238000000034 method Methods 0.000 title claims abstract description 83
- 210000004027 cell Anatomy 0.000 claims abstract description 183
- 238000004458 analytical method Methods 0.000 claims abstract description 68
- 102000011782 Keratins Human genes 0.000 claims abstract description 48
- 108010076876 Keratins Proteins 0.000 claims abstract description 48
- 238000003384 imaging method Methods 0.000 claims abstract description 33
- 239000012530 fluid Substances 0.000 claims abstract description 14
- 239000002356 single layer Substances 0.000 claims abstract description 13
- 206010028980 Neoplasm Diseases 0.000 claims description 82
- 201000011510 cancer Diseases 0.000 claims description 58
- 210000004369 blood Anatomy 0.000 claims description 35
- 239000008280 blood Substances 0.000 claims description 35
- 238000003556 assay Methods 0.000 claims description 31
- 101000738771 Homo sapiens Receptor-type tyrosine-protein phosphatase C Proteins 0.000 claims description 23
- 102100037422 Receptor-type tyrosine-protein phosphatase C Human genes 0.000 claims description 23
- 238000012512 characterization method Methods 0.000 claims description 17
- 238000001514 detection method Methods 0.000 claims description 14
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 claims description 10
- 238000004393 prognosis Methods 0.000 claims description 9
- 239000000758 substrate Substances 0.000 claims description 9
- 230000004043 responsiveness Effects 0.000 claims description 8
- 238000003745 diagnosis Methods 0.000 claims description 6
- 239000003153 chemical reaction reagent Substances 0.000 claims description 5
- 239000011521 glass Substances 0.000 claims description 5
- 238000005286 illumination Methods 0.000 claims description 5
- 239000003550 marker Substances 0.000 claims description 5
- 238000011269 treatment regimen Methods 0.000 claims description 5
- 230000006870 function Effects 0.000 claims description 4
- 239000002246 antineoplastic agent Substances 0.000 claims description 3
- 238000009104 chemotherapy regimen Methods 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 238000000576 coating method Methods 0.000 claims description 3
- 229940127089 cytotoxic agent Drugs 0.000 claims description 3
- 230000002209 hydrophobic effect Effects 0.000 claims description 3
- 230000004987 nonapoptotic effect Effects 0.000 claims description 3
- 230000001464 adherent effect Effects 0.000 claims description 2
- 238000000423 cell based assay Methods 0.000 claims description 2
- 230000005284 excitation Effects 0.000 claims description 2
- 239000002771 cell marker Substances 0.000 claims 2
- 238000013523 data management Methods 0.000 claims 2
- 238000013500 data storage Methods 0.000 claims 2
- 238000000116 DAPI staining Methods 0.000 claims 1
- 239000002458 cell surface marker Substances 0.000 claims 1
- 239000006059 cover glass Substances 0.000 claims 1
- 238000003860 storage Methods 0.000 abstract description 11
- 210000003855 cell nucleus Anatomy 0.000 abstract description 4
- 210000004940 nucleus Anatomy 0.000 description 42
- 239000000523 sample Substances 0.000 description 41
- 210000000265 leukocyte Anatomy 0.000 description 39
- 210000005266 circulating tumour cell Anatomy 0.000 description 24
- 210000002919 epithelial cell Anatomy 0.000 description 14
- 230000000877 morphologic effect Effects 0.000 description 13
- 239000013610 patient sample Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- 238000011282 treatment Methods 0.000 description 12
- 206010006187 Breast cancer Diseases 0.000 description 11
- 210000000805 cytoplasm Anatomy 0.000 description 11
- 230000001640 apoptogenic effect Effects 0.000 description 10
- 230000001086 cytosolic effect Effects 0.000 description 10
- 201000009030 Carcinoma Diseases 0.000 description 9
- 229940079593 drug Drugs 0.000 description 9
- 239000003814 drug Substances 0.000 description 9
- 206010027476 Metastases Diseases 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000035945 sensitivity Effects 0.000 description 8
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 7
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 7
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 206010061289 metastatic neoplasm Diseases 0.000 description 7
- 238000011160 research Methods 0.000 description 7
- 238000002560 therapeutic procedure Methods 0.000 description 7
- 210000004881 tumor cell Anatomy 0.000 description 7
- 206010060862 Prostate cancer Diseases 0.000 description 6
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 6
- 238000013459 approach Methods 0.000 description 6
- 230000002380 cytological effect Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 6
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 6
- 208000037819 metastatic cancer Diseases 0.000 description 6
- 208000011575 metastatic malignant neoplasm Diseases 0.000 description 6
- 208000010658 metastatic prostate carcinoma Diseases 0.000 description 6
- 201000002528 pancreatic cancer Diseases 0.000 description 6
- 208000008443 pancreatic carcinoma Diseases 0.000 description 6
- 238000012545 processing Methods 0.000 description 6
- 206010055113 Breast cancer metastatic Diseases 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 210000000481 breast Anatomy 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 238000005516 engineering process Methods 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 230000009401 metastasis Effects 0.000 description 5
- 230000001394 metastastic effect Effects 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 102100031650 C-X-C chemokine receptor type 4 Human genes 0.000 description 4
- 101000922348 Homo sapiens C-X-C chemokine receptor type 4 Proteins 0.000 description 4
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
- 230000014509 gene expression Effects 0.000 description 4
- 229940022353 herceptin Drugs 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 241000283707 Capra Species 0.000 description 3
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 description 3
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 201000001441 melanoma Diseases 0.000 description 3
- 238000012544 monitoring process Methods 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- 230000002093 peripheral effect Effects 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 210000002307 prostate Anatomy 0.000 description 3
- IGAZHQIYONOHQN-UHFFFAOYSA-N Alexa Fluor 555 Chemical compound C=12C=CC(=N)C(S(O)(=O)=O)=C2OC2=C(S(O)(=O)=O)C(N)=CC=C2C=1C1=CC=C(C(O)=O)C=C1C(O)=O IGAZHQIYONOHQN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- 102100032187 Androgen receptor Human genes 0.000 description 2
- 206010009944 Colon cancer Diseases 0.000 description 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 2
- 206010061818 Disease progression Diseases 0.000 description 2
- 206010061819 Disease recurrence Diseases 0.000 description 2
- 102100027100 Echinoderm microtubule-associated protein-like 4 Human genes 0.000 description 2
- 102100031983 Ephrin type-B receptor 4 Human genes 0.000 description 2
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 2
- 101001057929 Homo sapiens Echinoderm microtubule-associated protein-like 4 Proteins 0.000 description 2
- 101000892862 Homo sapiens Glutamate carboxypeptidase 2 Proteins 0.000 description 2
- 101000599951 Homo sapiens Insulin-like growth factor I Proteins 0.000 description 2
- 101001074727 Homo sapiens Ribonucleoside-diphosphate reductase large subunit Proteins 0.000 description 2
- 102100037852 Insulin-like growth factor I Human genes 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100021768 Phosphoserine aminotransferase Human genes 0.000 description 2
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 2
- 102100036320 Ribonucleoside-diphosphate reductase large subunit Human genes 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 108010080146 androgen receptors Proteins 0.000 description 2
- 210000000601 blood cell Anatomy 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- -1 cMET Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 238000013480 data collection Methods 0.000 description 2
- 230000005750 disease progression Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 102000015694 estrogen receptors Human genes 0.000 description 2
- 108010038795 estrogen receptors Proteins 0.000 description 2
- 238000003205 genotyping method Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000003278 mimic effect Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010827 pathological analysis Methods 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 210000005259 peripheral blood Anatomy 0.000 description 2
- 239000011886 peripheral blood Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 229920001481 poly(stearyl methacrylate) Polymers 0.000 description 2
- 102000003998 progesterone receptors Human genes 0.000 description 2
- 108090000468 progesterone receptors Proteins 0.000 description 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000003068 static effect Effects 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 201000003076 Angiosarcoma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 206010004146 Basal cell carcinoma Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 102000000905 Cadherin Human genes 0.000 description 1
- 108050007957 Cadherin Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010052358 Colorectal cancer metastatic Diseases 0.000 description 1
- 241000699800 Cricetinae Species 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 102100035186 DNA excision repair protein ERCC-1 Human genes 0.000 description 1
- 230000033616 DNA repair Effects 0.000 description 1
- 206010058314 Dysplasia Diseases 0.000 description 1
- 208000000471 Dysplastic Nevus Syndrome Diseases 0.000 description 1
- 101150029707 ERBB2 gene Proteins 0.000 description 1
- 108010055323 EphB4 Receptor Proteins 0.000 description 1
- 102000030797 EphB4 Receptor Human genes 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 201000008808 Fibrosarcoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 241000282575 Gorilla Species 0.000 description 1
- 206010018910 Haemolysis Diseases 0.000 description 1
- 101000876529 Homo sapiens DNA excision repair protein ERCC-1 Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008839 Kidney Neoplasms Diseases 0.000 description 1
- 206010024612 Lipoma Diseases 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 206010027406 Mesothelioma Diseases 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102000007298 Mucin-1 Human genes 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010061309 Neoplasm progression Diseases 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 206010061332 Paraganglion neoplasm Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000282405 Pongo abelii Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000004337 Salivary Gland Neoplasms Diseases 0.000 description 1
- 206010061934 Salivary gland cancer Diseases 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 206010066901 Treatment failure Diseases 0.000 description 1
- 206010046798 Uterine leiomyoma Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 208000020990 adrenal cortex carcinoma Diseases 0.000 description 1
- 210000004100 adrenal gland Anatomy 0.000 description 1
- 208000007128 adrenocortical carcinoma Diseases 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 230000025164 anoikis Effects 0.000 description 1
- 210000003567 ascitic fluid Anatomy 0.000 description 1
- 230000003190 augmentative effect Effects 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 201000000053 blastoma Diseases 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 1
- 201000007369 choroid plexus cancer Diseases 0.000 description 1
- 210000003040 circulating cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 238000000205 computational method Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- 238000007405 data analysis Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 210000002249 digestive system Anatomy 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 201000008184 embryoma Diseases 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 210000002889 endothelial cell Anatomy 0.000 description 1
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000003777 experimental drug Substances 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 206010016629 fibroma Diseases 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 201000011066 hemangioma Diseases 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000008588 hemolysis Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 238000010191 image analysis Methods 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 238000003125 immunofluorescent labeling Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 210000003963 intermediate filament Anatomy 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 201000010260 leiomyoma Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005249 lung adenocarcinoma Diseases 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000010339 medical test Methods 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 206010027191 meningioma Diseases 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 238000002705 metabolomic analysis Methods 0.000 description 1
- 208000011645 metastatic carcinoma Diseases 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 238000011206 morphological examination Methods 0.000 description 1
- 230000003562 morphometric effect Effects 0.000 description 1
- 238000013425 morphometry Methods 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 208000007538 neurilemmoma Diseases 0.000 description 1
- 208000004649 neutrophil actin dysfunction Diseases 0.000 description 1
- 210000004882 non-tumor cell Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000012758 nuclear staining Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 208000028776 osteoblastic osteosarcoma Diseases 0.000 description 1
- 201000008968 osteosarcoma Diseases 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 208000007312 paraganglioma Diseases 0.000 description 1
- 230000008447 perception Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 210000004910 pleural fluid Anatomy 0.000 description 1
- 230000002250 progressing effect Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 238000000575 proteomic method Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 201000009410 rhabdomyosarcoma Diseases 0.000 description 1
- 238000000518 rheometry Methods 0.000 description 1
- 210000003296 saliva Anatomy 0.000 description 1
- 206010039667 schwannoma Diseases 0.000 description 1
- HOZOZZFCZRXYEK-HNHWXVNLSA-M scopolamine butylbromide Chemical compound [Br-].C1([C@@H](CO)C(=O)OC2C[C@@H]3[N+]([C@H](C2)[C@@H]2[C@H]3O2)(C)CCCC)=CC=CC=C1 HOZOZZFCZRXYEK-HNHWXVNLSA-M 0.000 description 1
- 208000011571 secondary malignant neoplasm Diseases 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 238000012421 spiking Methods 0.000 description 1
- 230000007480 spreading Effects 0.000 description 1
- 238000003892 spreading Methods 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 230000000153 supplemental effect Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000005747 tumor angiogenesis Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 208000010579 uterine corpus leiomyoma Diseases 0.000 description 1
- 201000007954 uterine fibroid Diseases 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 201000011531 vascular cancer Diseases 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57492—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds localized on the membrane of tumor or cancer cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B21/00—Microscopes
- G02B21/34—Microscope slides, e.g. mounting specimens on microscope slides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L3/00—Containers or dishes for laboratory use, e.g. laboratory glassware; Droppers
- B01L3/50—Containers for the purpose of retaining a material to be analysed, e.g. test tubes
- B01L3/508—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above
- B01L3/5088—Containers for the purpose of retaining a material to be analysed, e.g. test tubes rigid containers not provided for above confining liquids at a location by surface tension, e.g. virtual wells on plates, wires
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/483—Physical analysis of biological material
- G01N33/4833—Physical analysis of biological material of solid biological material, e.g. tissue samples, cell cultures
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
-
- G—PHYSICS
- G02—OPTICS
- G02B—OPTICAL ELEMENTS, SYSTEMS OR APPARATUS
- G02B21/00—Microscopes
- G02B21/36—Microscopes arranged for photographic purposes or projection purposes or digital imaging or video purposes including associated control and data processing arrangements
- G02B21/365—Control or image processing arrangements for digital or video microscopes
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/08—Geometry, shape and general structure
- B01L2300/0809—Geometry, shape and general structure rectangular shaped
- B01L2300/0822—Slides
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
- B01L—CHEMICAL OR PHYSICAL LABORATORY APPARATUS FOR GENERAL USE
- B01L2300/00—Additional constructional details
- B01L2300/16—Surface properties and coatings
- B01L2300/161—Control and use of surface tension forces, e.g. hydrophobic, hydrophilic
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- General Physics & Mathematics (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- General Health & Medical Sciences (AREA)
- Optics & Photonics (AREA)
- Cell Biology (AREA)
- Multimedia (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Biochemistry (AREA)
- Medicinal Chemistry (AREA)
- Biotechnology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Clinical Laboratory Science (AREA)
- Oncology (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Hospice & Palliative Care (AREA)
- Tropical Medicine & Parasitology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Toxicology (AREA)
- Biophysics (AREA)
- Physiology (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Apparatus Associated With Microorganisms And Enzymes (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161568793P | 2011-12-09 | 2011-12-09 | |
| US61/568,793 | 2011-12-09 | ||
| PCT/US2012/068586 WO2013086428A1 (en) | 2011-12-09 | 2012-12-07 | Apparatus, system and method for identifying circulating tumor cells |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2015505966A true JP2015505966A (ja) | 2015-02-26 |
| JP2015505966A5 JP2015505966A5 (enExample) | 2016-03-31 |
Family
ID=48574948
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014546147A Pending JP2015505966A (ja) | 2011-12-09 | 2012-12-07 | 循環腫瘍細胞を特定するための装置、システム、及び方法 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20140329917A1 (enExample) |
| EP (1) | EP2788773A4 (enExample) |
| JP (1) | JP2015505966A (enExample) |
| KR (1) | KR20150008842A (enExample) |
| CN (1) | CN104428677A (enExample) |
| AU (1) | AU2012347526A1 (enExample) |
| BR (1) | BR112014013956A2 (enExample) |
| CA (1) | CA2858689A1 (enExample) |
| EA (1) | EA201491140A1 (enExample) |
| HK (1) | HK1201916A1 (enExample) |
| IL (1) | IL233007A0 (enExample) |
| MX (1) | MX2014006884A (enExample) |
| SG (1) | SG11201403041TA (enExample) |
| WO (1) | WO2013086428A1 (enExample) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20180019607A (ko) * | 2016-07-25 | 2018-02-26 | 가부시끼가이샤 옵토니쿠스 세이미쯔 | 세포의 슬라이드 글래스 표본 제작 장치, 세포의 슬라이드 글래스 표본 제작 방법, 및 dna 또는 rna의 추출 방법 |
| WO2018116465A1 (ja) * | 2016-12-22 | 2018-06-28 | 日立化成株式会社 | Ｈｅｒ２陽性癌細胞の検出方法 |
| JP2018136336A (ja) * | 2018-04-19 | 2018-08-30 | 日立化成株式会社 | 標準細胞液 |
| JP2021073437A (ja) * | 2015-04-21 | 2021-05-13 | ジェネンテック， インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| JP2021110664A (ja) * | 2020-01-14 | 2021-08-02 | 学校法人杏林学園 | 癌被験体の予後を予測する方法 |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2445204C (en) | 2002-10-16 | 2014-08-12 | Streck Laboratories, Inc. | Method and device for collecting and preserving cells for analysis |
| US11634747B2 (en) | 2009-01-21 | 2023-04-25 | Streck Llc | Preservation of fetal nucleic acids in maternal plasma |
| EP3290530B1 (en) | 2009-02-18 | 2020-09-02 | Streck Inc. | Preservation of cell-free nucleic acids |
| ES2556639T3 (es) | 2009-10-21 | 2016-01-19 | The Scripps Research Institute | Método para usar células no raras para detectar células raras |
| EP2704740B1 (en) | 2011-05-04 | 2016-10-05 | Streck, Inc. | Inactivated swine flu virus and methods of preparing it |
| US9396532B2 (en) * | 2012-11-15 | 2016-07-19 | Siemens Healthcare Diagnostics, Inc. | Cell feature-based automatic circulating tumor cell detection |
| EP4136972A1 (en) | 2013-07-24 | 2023-02-22 | Streck, Inc. | Compositions and methods for stabilizing circulating tumor cells |
| US9683938B2 (en) | 2013-07-31 | 2017-06-20 | The Regents Of The University Of California | Fluorescent imaging using a flatbed scanner |
| US10053692B2 (en) | 2013-10-21 | 2018-08-21 | The General Hospital Corporation | Methods relating to circulating tumor cell clusters and the treatment of cancer |
| EP3100047B1 (en) | 2014-01-27 | 2021-08-11 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for prostate cancer biomarkers |
| US20160011198A1 (en) * | 2014-01-27 | 2016-01-14 | Epic Sciences, Inc. | Detection of prostate specific membrane antigen (psma) expression on circulating tumor cells (ctc) |
| WO2015116828A1 (en) * | 2014-01-30 | 2015-08-06 | Epic Sciences, Inc. | Circulating tumor cell diagnostics for biomarkers predictive of resistance to androgen receptor (ar) targeted therapies |
| EP3108246B1 (en) | 2014-02-21 | 2019-10-09 | Epic Sciences, Inc. | Methods for analyzing rare circulating cells |
| CN104062428B (zh) * | 2014-07-09 | 2016-08-17 | 郑勤 | 一种检测循环肿瘤细胞的试剂盒 |
| HK1244848A1 (zh) * | 2014-12-10 | 2018-08-17 | 得克萨斯州大学系统董事会 | 使用基因组特异性探针的循环肿瘤和肿瘤干细胞检测 |
| US20160178630A1 (en) * | 2014-12-18 | 2016-06-23 | Creatv Microtech, Inc. | Methods for predicting overall survival of cancer patients based on numbers of circulating tumor cells |
| JP6737185B2 (ja) * | 2015-01-29 | 2020-08-05 | コニカミノルタ株式会社 | 相互作用する分子を有する血中細胞の同時検出方法 |
| US11168351B2 (en) | 2015-03-05 | 2021-11-09 | Streck, Inc. | Stabilization of nucleic acids in urine |
| KR102080107B1 (ko) * | 2015-05-14 | 2020-02-21 | 더 보오드 오브 트러스티스 오브 더 유니버시티 오브 일리노이즈 | 순환되는 종양세포를 바이오마커로 사용하여 암 치료요법의 효율을 모니터링 하는 방법 |
| WO2016207986A1 (ja) | 2015-06-24 | 2016-12-29 | 株式会社日立製作所 | 検査システム、検査装置、及び検査方法 |
| US20170145475A1 (en) | 2015-11-20 | 2017-05-25 | Streck, Inc. | Single spin process for blood plasma separation and plasma composition including preservative |
| US11506655B2 (en) | 2016-07-29 | 2022-11-22 | Streck, Inc. | Suspension composition for hematology analysis control |
| US9738937B1 (en) | 2017-03-31 | 2017-08-22 | Cellmax, Ltd. | Identifying candidate cells using image analysis |
| IT201700085439A1 (it) * | 2017-07-26 | 2019-01-26 | Tethis S P A | Metodo di immobilizzazione di campioni biologici a scopo analitico e diagnostico |
| ES2991437T3 (es) | 2017-10-19 | 2024-12-03 | Streck Llc | Composiciones para la regulación de la hemólisis y la coagulación y la estabilización de vesículas extracelulares |
| CN109887542A (zh) * | 2019-02-12 | 2019-06-14 | 嘉兴海云惠智医疗科技有限公司 | 一种基于云计算的肿瘤个体化基因检测智能解读系统 |
| CN110146704A (zh) * | 2019-03-28 | 2019-08-20 | 苏州举健生物科技有限公司 | 一种基于循环肿瘤细胞的用药及病理检测数据系统 |
| CN111323362A (zh) * | 2020-03-17 | 2020-06-23 | 宁波江丰生物信息技术有限公司 | 一种基于荧光切片的循环肿瘤细胞检测系统及检测方法 |
| CN114092934A (zh) * | 2020-07-31 | 2022-02-25 | 骏实生物科技(上海)有限公司 | 循环肿瘤细胞的分类方法 |
Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526785A (ja) * | 1998-08-07 | 2002-08-20 | バイオジェネックス ラボラトリーズ | 疎水性防壁によって規定された反応区域を有するスライド |
| JP2009500675A (ja) * | 2005-07-08 | 2009-01-08 | イコニシス インコーポレーテッド | スライド堆積室 |
| JP2009525468A (ja) * | 2006-01-30 | 2009-07-09 | ザ・スクリプス・リサーチ・インステイチユート | 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法 |
| JP2010512508A (ja) * | 2006-12-20 | 2010-04-22 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 量子ドットで染色された組織試料の定量的マルチ・スペクトル画像の分析 |
| WO2011093927A1 (en) * | 2010-01-27 | 2011-08-04 | Duke University | Biomarkers for circulating tumor cells |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3830721A1 (de) * | 1988-09-09 | 1990-03-22 | Michael Dr Menton | In labors, insbesondere in medizinischen labors, zu verwendender objekttraeger |
| CN2265982Y (zh) * | 1996-05-20 | 1997-10-29 | 中国农业大学 | 平底方槽型细胞显微操作载片 |
| US8192994B2 (en) * | 1998-02-10 | 2012-06-05 | Angros Lee H | Method of applying a biological specimen to an analytic plate |
| CN2377532Y (zh) * | 1999-06-10 | 2000-05-10 | 中国人民解放军第二军医大学 | 微量荧光细胞计数板 |
| AU2002249481A1 (en) * | 2000-10-25 | 2002-08-12 | Exiqon A/S | Open substrate platforms suitable for analysis of biomolecules |
| US7943093B2 (en) * | 2001-12-12 | 2011-05-17 | Erie Scientific Company | Cover slip |
| EP2155856A4 (en) * | 2007-06-05 | 2013-06-26 | Nanopoint Inc | SYSTEMS AND METHODS OF CELL TRAY |
| CN201184866Y (zh) * | 2008-02-26 | 2009-01-21 | 强实贸易(上海)有限公司 | 定量细胞计数系统装置 |
| WO2010045949A2 (en) * | 2008-10-21 | 2010-04-29 | Chemometec A/S | A method and apparatus for analysis of a particle |
-
2012
- 2012-12-07 EP EP12855719.6A patent/EP2788773A4/en not_active Withdrawn
- 2012-12-07 KR KR20147018924A patent/KR20150008842A/ko not_active Withdrawn
- 2012-12-07 SG SG11201403041TA patent/SG11201403041TA/en unknown
- 2012-12-07 US US14/363,290 patent/US20140329917A1/en not_active Abandoned
- 2012-12-07 HK HK15102251.3A patent/HK1201916A1/xx unknown
- 2012-12-07 WO PCT/US2012/068586 patent/WO2013086428A1/en not_active Ceased
- 2012-12-07 CN CN201280069331.XA patent/CN104428677A/zh active Pending
- 2012-12-07 CA CA2858689A patent/CA2858689A1/en not_active Abandoned
- 2012-12-07 AU AU2012347526A patent/AU2012347526A1/en not_active Abandoned
- 2012-12-07 JP JP2014546147A patent/JP2015505966A/ja active Pending
- 2012-12-07 MX MX2014006884A patent/MX2014006884A/es unknown
- 2012-12-07 EA EA201491140A patent/EA201491140A1/ru unknown
- 2012-12-07 BR BR112014013956A patent/BR112014013956A2/pt not_active Application Discontinuation
-
2014
- 2014-06-08 IL IL233007A patent/IL233007A0/en unknown
Patent Citations (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2002526785A (ja) * | 1998-08-07 | 2002-08-20 | バイオジェネックス ラボラトリーズ | 疎水性防壁によって規定された反応区域を有するスライド |
| JP2009500675A (ja) * | 2005-07-08 | 2009-01-08 | イコニシス インコーポレーテッド | スライド堆積室 |
| JP2009525468A (ja) * | 2006-01-30 | 2009-07-09 | ザ・スクリプス・リサーチ・インステイチユート | 循環腫瘍細胞の検出方法および哺乳類対象における癌の診断方法 |
| JP2010512508A (ja) * | 2006-12-20 | 2010-04-22 | ベンタナ・メデイカル・システムズ・インコーポレーテツド | 量子ドットで染色された組織試料の定量的マルチ・スペクトル画像の分析 |
| WO2011093927A1 (en) * | 2010-01-27 | 2011-08-04 | Duke University | Biomarkers for circulating tumor cells |
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2021073437A (ja) * | 2015-04-21 | 2021-05-13 | ジェネンテック， インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| JP7022191B2 (ja) | 2015-04-21 | 2022-02-17 | ジェネンテック， インコーポレイテッド | 前立腺がんの分析のための組成物及び方法 |
| KR20180019607A (ko) * | 2016-07-25 | 2018-02-26 | 가부시끼가이샤 옵토니쿠스 세이미쯔 | 세포의 슬라이드 글래스 표본 제작 장치, 세포의 슬라이드 글래스 표본 제작 방법, 및 dna 또는 rna의 추출 방법 |
| KR102064049B1 (ko) | 2016-07-25 | 2020-01-08 | 가부시끼가이샤 옵토니쿠스 세이미쯔 | 세포의 슬라이드 글래스 표본 제작 방법 |
| WO2018116465A1 (ja) * | 2016-12-22 | 2018-06-28 | 日立化成株式会社 | Ｈｅｒ２陽性癌細胞の検出方法 |
| JP2018136336A (ja) * | 2018-04-19 | 2018-08-30 | 日立化成株式会社 | 標準細胞液 |
| JP2021110664A (ja) * | 2020-01-14 | 2021-08-02 | 学校法人杏林学園 | 癌被験体の予後を予測する方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2788773A1 (en) | 2014-10-15 |
| CA2858689A1 (en) | 2013-06-13 |
| MX2014006884A (es) | 2015-06-02 |
| EP2788773A4 (en) | 2015-09-09 |
| BR112014013956A2 (pt) | 2017-06-13 |
| IL233007A0 (en) | 2014-07-31 |
| HK1201916A1 (en) | 2015-09-11 |
| WO2013086428A1 (en) | 2013-06-13 |
| CN104428677A (zh) | 2015-03-18 |
| EA201491140A1 (ru) | 2014-11-28 |
| SG11201403041TA (en) | 2014-08-28 |
| KR20150008842A (ko) | 2015-01-23 |
| US20140329917A1 (en) | 2014-11-06 |
| AU2012347526A1 (en) | 2014-07-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015505966A (ja) | 循環腫瘍細胞を特定するための装置、システム、及び方法 | |
| US20230085158A1 (en) | Method of using non-rare cells to detect rare cells | |
| US10613089B2 (en) | Method of using non-rare cells to detect rare cells | |
| JP6109464B2 (ja) | 生体サンプル中の希有な事象の分析のための高感度マルチパラメータ法 | |
| US10254286B2 (en) | Methods for detecting 5T4-positive circulating tumor cells and methods of diagnosis of 5T4-positive cancer in a mammalian subject | |
| EP3924733B1 (en) | Ccr5-based methods for predicting overall and progression free survival in subjects having cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151204 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20151204 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20160202 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20161005 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20161101 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20170127 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20170627 |